Multi-omics datasets quantify complementary aspects of molecular biology and thus pose 14 challenges to data interpretation and hypothesis generation. ActivePathways is an 15 integrative method that discovers significantly enriched pathways across multiple omics 16 datasets using a statistical data fusion approach, rationalizes contributing evidence and 17 highlights associated genes. We demonstrate its utility by analyzing coding and non-18 coding mutations from 2,583 whole cancer genomes, revealing frequently mutated 19 hallmark pathways and a long tail of known and putative cancer driver genes. We also 20 studied prognostic molecular pathways in breast cancer subtypes by integrating genomic 21 and transcriptomic features of tumors and tumor-adjacent cells and found significant 22 associations with immune response processes and anti-apoptotic signaling pathways. 23
Introduction 27
Pathway enrichment analysis is an essential step for interpreting high-throughput (omics) data 28 that uses current knowledge of genes and biological processes. A common application 29 determines statistical enrichment of molecular pathways, biological processes and other 30 functional annotations in long lists of candidate genes 1,2 . Genomic, transcriptomic, proteomic and 31 epigenomic experiments emphasize distinct and complementary aspects of underlying biology 32 and are best analyzed integratively, as is now routinely done in large-scale projects such as The 33
Cancer Genome Atlas (TCGA) 3 , Clinical Proteome Tumor Analysis Consortium (CPTAC), 34
International Cancer Genome Consortium (ICGC) 4 , Genotype-Tissue Expression (GTEx) 5 and 35 others. Thus, simultaneous analysis of multiple candidate gene lists for characteristic pathways 36 is increasingly needed. Numerous approaches are available for interpreting single gene lists. For 37 example, the GSEA algorithm can detect up-and down-regulated pathways in gene expression 38 datasets 6 . Web-based methods such as Panther 7 , ToppCluster 8 and g:Profiler 9 detect significantly 39 enriched pathways amongst ranked or unranked gene lists and are generally applicable to genes 40 and proteins from various analyses. Some approaches allow analysis of multiple input gene lists 41 however these primarily rely on visualization rather than data integration to evaluate the 42 contribution of distinct gene lists towards each detected pathway 8, 9 . Finally, no methods are 43 available for unified pathway analysis of coding and non-coding mutations from whole-genome 44 sequencing (WGS) data, or integrating these with other types of DNA aberrations such as copy 45 number changes and balanced genomic rearrangements. We report the development of the 46 ActivePathways method that uses data fusion techniques to address the challenge of integrative 47 pathway analysis of multi-omics data. We demonstrate the method by analyzing known and 48 candidate cancer driver genes with coding and non-coding somatic mutations in 2,583 whole 49 cancer genomes of the ICGC-TCGA PCAWG project 10,11 , prognostic pathways in breast cancer 50 subtypes, and regulatory networks of tissue transcriptomes using the GTEx 5 compendium. 51
Characterization of genes and somatic mutations that drive oncogenesis is a central goal of 52 cancer genomics research. Cancer genomes are characterized by few frequently mutated pan-53 cancer drivers such as TP53, less-frequent drivers with primarily tissue-specific effects and 54 numerous infrequently mutated genes often referred to as the long tail. The majority of currently 55 known driver mutations affect protein-coding sequence 12 and only few high-confidence non-56 coding drivers have been found, such as the mutation hotspots in the TERT promoter 13 . Discovery 57 of non-coding driver mutations is a major goal of large cancer whole genome sequencing efforts 58 such as PCAWG 10, 11 . Pathway and network analysis of cancer mutations is a powerful approach that uses knowledge of coding driver genes and their pathway annotations as priors to assist in 60 detection of weak driver variants including those in the non-coding genome 1 . The PCAWG project 61 has produced a consensus dataset of predicted protein-coding driver genes (CDS) and non-62 coding regions of 5' and 3' untranslated elements (UTRs), promoters and enhancers of protein-63 coding genes across 2,583 whole cancer genomes of multiple cancer types 14 . Driver gene p-64 values in the dataset reflect the frequency and functional impact of somatic single nucleotide 65 variants (SNVs) and small insertions-deletions (indels) in these protein-coding and non-coding 66 genomic regions. Here we used our ActivePathways method to interpret these driver predictions 67 with pathway information including biological processes of Gene Ontology 15 and molecular 68 pathways defined by Reactome 16 . Two further case studies focused on prognostic molecular 69 pathways of breast cancer through integration of genomic and transcriptional alterations, and 70 gene regulatory networks associated with organ growth control in healthy human tissues. 71
72
Results 73
Multi-omics pathway enrichment analysis with ActivePathways 74
ActivePathways is a simple four-step method that extends our earlier work 9 (Figure 1) . It requires 75 two input datasets. First, a table of gene p-values contains multiple p-values for every gene 76 representing different types of evidence such as gene significance in distinct omics experiments. 77
These could include p-values evaluating the significance of differential gene expression in tissues 78 of interest, gene essentiality, mutation or copy number alteration burden, and many others. 79
Second, a collection of gene sets represents molecular pathways, biological processes and other 80 gene annotations we refer to as pathways. Depending on the hypothesis, pathways may also 81 include other types of gene sets such as targets of transcription factors or microRNAs. In the first 82 step of ActivePathways, we derive an integrated gene list that aggregates significance from all 83 types of evidence for each input gene. The integrated gene list is compiled by fusion of gene 84 significance from different types of evidence using the Brown's extension 17 of the Fisher's 85 combined probability test, which conservatively adjusts for overall correlations of p-values in 86 estimating the overall significance of every gene. The integrated input gene list is then ranked by 87 decreasing significance and filtered using a lenient cut-off to capture a long tail of candidate genes 88 and to filter the bulk of insignificant ones (unadjusted Pgene<0.1). The integrated gene list is 89 analyzed with a ranked hypergeometric test for each pathway to capture smaller pathways tightly 90 associated with few top-ranking genes and broader processes with abundant albeit weaker 91 signals from larger subsets of input genes. The stringent family-wise multiple testing correction method by Holm 18 is applied across pathways to reduce false positives (Qpathway<0.05). In the third 93 step, candidate gene lists corresponding to distinct types of evidence are separately evaluated 94 using the above procedure. This step determines which pathways are significantly supported by 95 each of the input omics datasets and also reveals corresponding genes in each pathway. 96 Importantly, the step also highlights pathways that are only found through data integration and 97 are not apparent in any single type of omics evidence alone. In the fourth step, the method 98 provides input files for Enrichment Map 19 for visualizing and reducing the redundant set of all 99 detected pathways to a narrower, focused network of biological themes. 100 
114
Pathway analysis of coding and non-coding mutations in 2,500 whole cancer genomes 115
We performed integrative pathway analysis of coding and non-coding driver predictions across 116 29 cancer patient cohorts of histological tumor types and 18 meta-cohorts combining multiple 117 types of tumors, with 47 cohorts in total ( Supplementary Table 1 ). ActivePathways found at least 118 one significantly enriched process or pathway in the majority of these cohorts (42/47 or 89%, 119
Qpathway<0.05) (Figure 2a ). We analyzed the omics evidence supporting predictions of enriched 120 pathways and found that most cohorts showed enrichments in pathways supported by protein-121 coding driver scores of genes (37/47 or 79%). This serves as a positive control since the majority 122 of currently known cancer driver genes have frequent protein-coding mutations. 123 Non-coding mutations in genes also contributed to the discovery of frequently mutated biological 124 processes and pathways: 24/47 cohorts (51%) showed significantly enriched pathways that were 125 apparent when only analyzing non-coding driver scores separately for UTRs, promoters or 126 enhancers. The majority of cohorts (41/47 or 87%) revealed enriched pathways that were 127 apparent in the integrated gene list but not in any gene lists ranked by element-specific driver 128 scores, emphasizing the value of our integrative approach. As expected, cohorts with more patient 129 tumor samples generated more significantly enriched pathways (Spearman ρ=0.74, P=2.3x10 -9 ; 130 Supplementary Figure 1 ), suggesting that larger datasets are better powered to distinguish 131 rarely mutated genes involved in biological pathways and processes. Discovery of pathways 132 enriched in non-coding mutations suggests that pathway analysis is an attractive strategy for 133 illuminating the dark matter of the non-coding cancer genome. 
160
We studied the adenocarcinoma meta-cohort with 1,773 samples of 16 tumor types whose 161 integrated list of 432 candidate genes (unadjusted Pgene<0.1) associated with 526 significantly 162 enriched pathways (Qpathway<0.05) (Figure 2b) . As expected, the majority of pathways were only 163 supported by genes with frequent coding mutations (328/526 or 62%). However, 101 pathways 164 were supported by both coding and non-coding gene mutations, 72 were only apparent in the 165 integrated analysis of all evidence, and 25 were only found among genes with significant non-166 coding mutations, thus expanding the set of candidate driver mutations in the non-coding cancer 167 genome and demonstrating the value of integrative pathway analysis. 168
The major biological themes with frequent protein-coding mutations included hallmark cancer 169 processes like apoptotic signaling pathway (24 genes; Qpathway=4.3x10 -5 ) and mitotic cell cycle (8 170 genes; Qpathway=0.0026), and additional biological processes such as chromatin modification and 171 RNA splicing that are increasingly recognized in cancer biology. Thus, our method captures the 172 expected cancer pathways among driver genes with protein-coding mutations as positive controls.
In contrast to these solely protein-coding driver associations, a large group of developmental 174 processes and signal transduction pathways was enriched in genes with coding as well as non-175 coding mutations; for example embryo development process was supported by mutations in 176 exons, 3'UTRs and gene promoters (68 genes; Qpathway=2.9x10 -12 ), while repression of WNT target 177 genes was only apparent in the integrated analysis of coding and non-coding mutations but not 178 in either alone (5 genes, Qpathway=0.016; REAC:4641265). Thus, our method evaluates 179 contribution of omics evidence towards pathway enrichments and finds additional associations 180 that are not apparent in any provided dataset. 181 182 ActivePathways highlights pathway-associated cancer genes in the long tail of infrequent 183
non-coding mutations 184
We focused on a group of processes involved in kidney development that were only detected in 185 the integrated analysis (Figure 2c-d) . ActivePathways found 18 genes involved in these 186 processes, only five of which were predicted as driver genes in the consensus driver analysis of 187 the PCAWG project 14 . Additional known cancer genes included the oncogene MYC with 13 188 patients with 3'UTR mutations (PUTR3=4.8x10 -4 ; QUTR3=0.42), the transcription factor SMAD3 of 189 the TGF-β pathway with 14 patients with protein-coding mutations (PCDS=4.0x10 -4 ; QCDS=0.37) 190 and the growth inhibitory tumor suppressor gene TSC1 with 23 patients with protein-coding 191 mutations (PCDS=1.4x10 -4 ; QCDS=0.17) as well as candidate cancer genes such as IQGAP1 with 192 10 patients with promoter mutations (Ppromoter=8.2x10 -4 ; Qpromoter=0.62) that encodes a signaling 193 protein that regulates cell motility and morphology. The additional genes remained below the 194 FDR-adjusted significance cut-off in the gene-focused consensus driver analysis, however were 195 found by ActivePathways due to pathway associations with frequently mutated developmental 196 genes. These results highlight the potential of our method to find known and candidate cancer 197 genes with rare coding and non-coding driver mutations through pathway-driven data integration. 198
We evaluated 333 candidate driver genes from the pathway analysis of the adenocarcinoma 199 cohort (Figure 2e) . These included as positive controls 60/64 significantly mutated genes 200 identified in the PCAWG consensus driver analysis 14 , and an additional 47 genes of the COSMIC 201 Cancer Gene Census database 12 , significantly more than expected by chance alone (seven 202 genes expected, Fisher's exact P=4.0x10 -24 ), including MYC, IDH1, NF1, and BCL9. Additional 203 genes were detected for several reasons. First, the integrated gene list was filtered using a lenient 204 statistical cut-off (Pgene<0.1) compared to a more stringent gene-focused driver analysis 205 below the significance threshold in the driver analysis. Second, the integration procedure 207 combined multiple weaker p-values (coding regions, promoters, UTRs, enhancers) to a single 208 stronger p-value for 17/333 pathway-associated genes including six cancer genes (HNRNPA2B1, 209 STAG2, TCF7L2, SUZ12, CLTC, ZNF521) and improved the overall ranking of 220/333 genes 210 among the input data, better explaining their membership in pathways and processes. However, 211 a majority of all genes showed reduced significance after the integration procedure and were 212 excluded from the pathway analysis, as the Brown combined p-value remained below the 213 significance cut-off compared to any individual p-values of mutations in coding and non-coding 214 regions of genes (3,112/3,543 or 88% genes with unadjusted min(Pgene)<0.1 showed unadjusted 215
Brown Pgene>0.1). Fourth, the evidence evaluation step of the method identified pathway 216 enrichments in gene lists ranked by individual sources of evidence and highlighted additional 217 genes that did not pass significance cut-offs of the integration procedure. Thus, ActivePathways 218 finds additional cancer genes in the long tail of mutations that are highlighted due to their pathway 219 associations but remain below the significance cut-off in the gene-by-gene analysis. 220 221
Benchmarking demonstrates the robustness and sensitivity of ActivePathways 222
We carefully benchmarked ActivePathways using multiple approaches. First, we compared its 223 performance with six diverse methods used in the PCAWG pathway and network analysis working 224 group 20 (Hierarchical HotNet 21,22 , SSA−ME 23 , NBDI 24 , induced subnetwork analysis 22 , 225
CanIsoNet [Kahraman et al, in prep] , and hypergeometric test). The methods used molecular pathway and 226 network information to analyze the PCAWG dataset of predicted cancer driver genes 14 , and a 227 subsequent consensus procedure derived pathway-implicated driver (PID) gene lists with coding 228 (PID-C) and non-coding (PID-N) mutations based on a majority vote. Our method recovered PID-229 C and PID-N gene lists with the highest accuracy: 100% of coding driver genes (87/87) and 85% 230 of non-coding candidates (79/93) were detected (Figure 2f) . 231
We evaluated the robustness of ActivePathways to parameter variations and missing data. We 232 varied the parameter Pgene that determines the ranked gene lists used in the pathway enrichment 233 analysis (default threshold Pgene<0.1). The majority of cohorts (40/47 or 85%) retrieved 234 significantly enriched pathways even with a considerably more stringent threshold (Pgene<0.001), 235 however 67% fewer pathways were found compared to the default threshold in the median cohort 236 (Supplementary Figure 2) . We then evaluated the robustness of ActivePathways to missing data 237 by randomly removing subsets of driver scores from the initial dataset. Even when removing 50% 238 of gene driver scores with P<0.001, the majority of cohorts (37/47 or 79%) were found to have at least one significantly enriched pathway however 66% fewer pathways were found on average 240 ( Supplementary Figure 3) . 241
We tested ActivePathways with data simulations through 1,000 datasets for each of 47 patient 242 cohorts and found no significant pathways in 92% of simulations (Supplementary Figure 4) . 243
Simulated data were obtained by randomly reassigning driver scores to different genomic 244 elements, a conservative approach that disrupts gene and pathway annotations while retaining 245 strong scores in the data. The median family-wise false discovery rate across cohorts (7.2%) 246 slightly exceeded the applied multiple testing correction (Q<0.05). Higher rates were observed in 247 cohorts including melanoma tumors, potentially due to abundant promoter mutations caused by 248 impaired nucleotide excision repair in protein-bound genomic regions 25 . We evaluated quantile-249 quantile (QQ) plots of pathway-based p-values from ActivePathways and found that p-values from 250 observed gene scores often deviated from the expected uniform distribution and appeared 251 statistically inflated (Supplementary Figure 5) . However, p-values derived from simulated gene 252 scores showed no inflation in our simulations. Anticipating that the strongest cancer driver scores 253 associate with protein-coding sequence, we studied datasets with simulated protein-coding gene 254 scores and true non-coding scores. As expected, these partially simulated datasets expectedly 255 showed less p-value inflation, suggesting that highly significant known cancer genes involved in 256 QluminalA= 0.016, 231 genes) (Figure 3c) . Anti-apoptotic pathways were only detected in the 299 integrative analysis and not in genomic and transcriptomic gene signatures separately. Among 300 the genes negatively regulating apoptosis, DUSP1 provided the strongest prognostic signal in 301 HER2-enriched breast cancers. This was apparent in the molecular stratification of samples by 302 mRNA of tumor cells (log-rank PTC=0.019, HR=1.5) and tumor-adjacent cells (PTAC=8.3x10 -4 , 303 HR=1.83) as well as gene copy number amplifications (PCNA=9.8x10 -4 , HR=2.8) (Figure 3d) . DUSP1 encodes a phosphatase signaling protein of the MAPK pathway that is over-expressed in 305 malignant breast cancer cells and inhibits apoptotic signaling 31 . HER2 over-expression is known 306 to suppress apoptosis in breast cancer 30 . Anti-apoptotic signaling is a hallmark of cancer and 307 expectedly associated with worse patient prognosis. 308
ActivePathways also identified prognostic pathway associations in single subtypes of breast 309 cancer. For example, the prognostic genes for luminal-B subtype were enriched for chromosome 310 segregation (QluminalB=0.017, 41 genes) and related biological processes of GO. In agreement with 311 this finding, problems with chromosome segregation have been associated with worse outcome 312 in breast cancer 32 . As another example, luminal-A breast cancers were associated with prognosis 313 in ribosomal and RNA processing genes, such as ribosome biogenesis (QluminalA=6.9x10 -10 , 60 314 genes), and rRNA metabolic process (QluminalA=1.8x10 -13 , 64 genes). Although not described 315 specifically in the luminal-A subtype, ribosomal mRNA abundance has been shown to be 316 prognostic in breast cancer as a marker of cell proliferation 33,34 . In summary, ActivePathways can 317 be used for integrating clinical data with multi-omics information of molecular alterations. Such 318 analyses can provide leads for functional studies and biomarker development. 
Co-expression analysis of Hippo master regulators across 54 human tissues recovers 333 associated biological processes and genes 334
To study the use of ActivePathways in the context of healthy human tissues, we analyzed the 335 dataset of 11,688 transcriptomes of 54 tissues from the GTEx project 5 , focusing on the Hippo 336 signaling pathway involved in organ size control, tissue homeostasis and cancer 35, 36 . We studied 337 gene co-expression networks downstream of YAP and TAZ, the two master transcription factors 338 of Hippo signaling, encoded by YAP1 and WWTR1. YAP and TAZ are the evolutionarily 339
conserved key effectors of the Hippo signaling in mammals. Inhibition of YAP/TAZ-mediated 340 transcription regulates organ size control and tissue homeostasis in response to a wide range of 341 intracellular and extracellular signals including cell-cell interactions, cell polarity, mechanical cues, 342 ligands of G-protein-coupled receptors, and cellular energy status. We retrieved 2,117 putative 343
Hippo transcriptional target genes that showed significant positive co-expression with either or 344 both of the transcripts of YAP and TAZ across the human tissues in the GTEx dataset 345 (Qgene<0.05). We used a robust rank aggregation method 37 and retrieved transcriptional targets 346 that were co-expressed with YAP or TAZ in a relatively large number of human tissues. 347
Analysis of the target genes using ActivePathways resulted in 101 significantly enriched pathways 348 (Qpathway<0.05), including 39 supported by both sets of target genes, 37 supported by YAP1 349 targets, 18 supported by TAZ targets, and seven only apparent in the integrated list of target 350 genes (Figure 4) Integrative pathway enrichment analysis helps distill thousands of high-throughput measurements 374 to a smaller number of pathways and biological themes that are most characteristic of the 375 experimental data, ideally leading to mechanistic insights and novel candidate genes for follow-376 up studies. The primary advantage of our method is the fusion of gene significance across multiple omics datasets. This allows us to identify additional pathways and processes that are not apparent 378 individually in any analyzed dataset. In our example of cancer driver discovery, pathway analysis 379 is complementary to gene-focused driver discovery as it also focuses on sub-significant genes 380 with coding and non-coding mutations clustered into known and novel biological processes of 381 cancer. In the clinical analysis of breast cancer subtypes, we find prognostic genes and pathways 382 active in tumor cells, the microenvironment, or both. A subset of these findings, such as anti-383 apoptotic signaling, is only apparent through data integration. 384
Our general pathway analysis strategy is applicable to diverse kinds of omics datasets where 385 well-calibrated p-values are available for the entire set of genes or proteins. One may study a 386 series of genomic, transcriptomic, or proteomic experiments or combine these into a multi-omics 387 analysis. Data from epigenomic experiments and genome-wide association studies can be 388 analyzed after genome-wide signals have been appropriately mapped to genes. Clinical and 389 phenotypic information of patients can be also included through association and survival statistics. 390
Our method is expected to work with unadjusted as well as multiple-testing adjusted p-values, 391 however it is primarily intended for un-adjusted p-values for increased sensitivity. P-value 392 adjustment for multiple testing is conducted at the pathway level rather than at a gene level. P-393 values from omics datasets are easier to interpret than raw signals as gene-based p-values are 394 expected to account for experimental and computational biases specific to each analyzed dataset, 395 while accounting for multi-omics factors comprehensively in a single generally applicable 396 pathway-based model would be likely impossible. In our example of cancer driver discovery, 397 appropriately computed p-values account for confounding factors of somatic mutations such as 398 gene sequence length and nucleotide content, mutation signatures active in different types of 399 tumors 38 and biological cofactors of mutation frequency such as transcription and replication 400 timing 39 , while pathway analysis of mutation counts or frequencies would maintain such biases in 401 results. 402
Our analysis comes with important caveats. First, we only evaluate genes annotated in pathway 403 databases that have variable coverage, rely on frequent data updates 40 and may miss novel 404 sparsely annotated candidate genes. The most general pathway enrichment analysis considers 405 biological processes and molecular pathways however many kinds of gene sets available in 406 resources such as MSigDB 41 can be used to expand the scope of ActivePathways. Second, 407 pathway information is highly redundant and analysis of rich omics datasets often results in many 408 significant results reflecting the same underlying pathway. We address this redundancy by 409 visualizing and summarizing pathway results as enrichment maps 2,19 that help distill general biological themes comprised of multiple similar pathways and processes. Statistical inflation of 411 results accompanied by biological redundancy is addressed by a stringent multiple testing 412 correction. Third, the analysis treats pathways as gene sets and does not consider their 413
interactions. This expands the scope of our analysis to a wider repertoire of pathways and 414 processes as reliable mechanistic interactions are often context-specific and limited to a small 415 subset of well-studied signaling pathways. Several methods such as HotNet 21 , PARADIGM 42 and 416 GeneMania 43 model pathways and omics datasets through gene and protein interactions. 417
Translation of discoveries into improved human health through actionable mechanistic insights, 418 biomarkers, and molecular therapies is a long-standing goal of biomedical research. Next-419 generation projects such as ICGC-ARGO (https://www.icgcargo.org/) aim to collect multi-omics 420 datasets with detailed clinical profiles of patients and thus present novel challenges for pathway 421 and network analysis techniques. In summary, ActivePathways is integrative pathway analysis 422 method that improves systems-level understanding of cellular organization in health and disease. 423
Methods 424
Integrated and evidence-based gene lists. The main input of ActivePathways is a matrix of p-425 values where rows include all genes of a genome and columns correspond to omics datasets. To 426 interpret multiple omics datasets, a combined p-value was computed for each gene using a data 427 fusion approach, resulting in an integrated gene list. The integrated gene list was computed gene- where Ppathway stands for the hypergeometric P-value of the pathway enrichment at the optimal 446 sub-list of the significance-ranked candidate genes, G represents the length of the optimal sub-447 list, i.e. the number of top genes from the input gene list, N is the number of protein-coding genes 448 with annotations in the pathway database, i.e., in Gene Ontology and Reactome, K is the total 449 number of genes in a given pathway, n is the number of genes in a given gene sub-list considered, 450 and k is the number of pathway genes in the considered sub-list. For a conservative estimate of 451 pathway enrichment, we considered as background N the universe of genes contained in pathway 452 databases and ontologies rather than the complete repertoire of protein-coding genes. To obtain 453 candidate genes involved in the pathway of interest, we intersected pathway genes with the 454 optimal sub-list of candidate genes. The ranked hypergeometric p-value was computed for all 455 pathways and resulting p-values were corrected for multiple testing using the conservative Bonferroni family-wise error rate (FWER) method 18 . Significant pathways were reported (Q<0.05). 457
Evaluating omics evidence of enriched pathways. The integrated gene list was analyzed the 458 using ranked hypergeometric test and enriched pathways were reported as results. Each 459 evidence-based gene list representing an omics dataset was also analyzed for enriched pathways 460 with the ranked hypergeometric test. Pathways found in the integrated gene list were labelled for 461 supporting evidence if they were also found as significant in any evidence-based gene list. A 462 pathway was considered to be found only through data integration and labelled as combined-only 463 if it was identified as enriched in the integrated gene list but was not identified as enriched in any 464 of the evidence-based gene lists at equivalent significance cutoffs (Q<0.05). Each detected 465 pathway was additionally annotated with pathway genes apparent in the optimal sub-list of 466 candidate genes, separately for the integrated gene list and each evidence-based gene list. 467
Gene scores of cancer mutations. We analyzed p-values of genes reflecting their statistical 468 significance as candidate cancer drivers for multiple cohorts of cancer patients with whole 469 genome sequencing data. The scores were compiled in the driver discovery analysis of the 470 PCAWG project as a consensus of multiple independent methods 14 . The input matrix of gene 471 scores (P-values) included all protein-coding genes as rows and their genomic elements as 472 columns (exons, 5' and 3' untranslated regions (UTRs), promoters, enhancers). Elements with 473 missing p-values were assigned P=1. Genes with multiple enhancers were assigned the score of the most significant enhancer, and enhancers with more than five associated genes were 475 excluded prior to selection. 476
Pathways and processes. We used gene sets corresponding to biological processes of Gene 477
Ontology 15 and molecular pathways of the Reactome database 16 downloaded from the g:Profiler 478 web server 9 . Large general gene sets with more than a thousand genes and small specific gene 479 sets with less than five genes were excluded. 480 Enrichment map visualization. ActivePathways provides input files for the EnrichmentMap 481 app 19 of Cytoscape 45 for network visualization of similar pathways and their coloring according to 482 supporting omics evidence. Enrichment maps for adenocarcinoma driver mutations, breast 483 cancer prognostics, and Hippo transcriptional networks were visualized with stringent pathway 484 similarity scores (Jaccard and overlap combined coefficient 0.6) and manually curated for the 485 most representative groups of similar pathways and processes. Singleton pathways that were 486 redundant with larger groups of pathways were discarded. Coloring of pathways in the 487 adenocarcinoma enrichment map was rearranged by merging colors of pathways supported by 488 non-coding mutation scores of promoters, enhancers and/or UTRs into one group. 489
Analysis of coding and non-coding mutations of the PCAWG pan-cancer dataset. We used 490
ActivePathways to analyze driver predictions of coding and non-coding mutations across >2,500 491 whole cancer genomes of the ICGC-TCGA PCAWG Project. P-values of driver predictions were 492 computed separately for protein-coding sequences, promoters, enhancers and untranslated 493 regions (UTR3, UTR5) in the PCAWG driver discovery study by Rheinbay et al 14 across multiple 494 subsets of samples representing histological tumor types and pan-cancer cohorts. We used gene-495 enhancer mapping predictions provided by PCAWG, excluded enhancers with more than five 496 target genes, and selected the most significant enhancer for each gene, if any. Unadjusted p-497 values for coding sequences, promoters, enhancers and UTRs were compiled as input matrices 498 and analyzed as described above. Missing p-values were interpreted as ones. Results from 499 ActivePathways were validated with two lists of cancer genes. Predicted drivers from the gene-500 focused PCAWG driver analysis 14 were selected as statistically significant findings (Q<0.05) 501 following a stringent multiple testing correction spanning all types of elements (exons, UTRs, 502 promoter, enhancers). The curated list of known cancer genes was retrieved from the COSMIC 503 Cancer Gene Census (CGC) database 12 . One-tailed Fisher's exact tests were used to estimate 504 enrichment of these genes using all protein-coding genes as background. 505
Analysis of prognostic genes in breast cancer. ActivePathways was used to evaluate 506 prognostic pathways in breast cancer using multiple types of omics data. mRNA gene expression data and gene copy number alteration (CNA) data of the were derived from the METABRIC cohort 508 of 1,991 patients with a single primary fresh frozen breast cancer specimen each 26 dichotomized based on mRNA abundance. Dichotomization was either based on the median 518 mRNA abundance for that gene or a fixed value of 6.5. Based on the mRNA abundance 519 distribution of genes on the Y chromosome in female samples, 6.5 was estimated as the threshold 520 for noise for non-expressed genes. Median dichotomization was used if the median was above 521 6.5 or if there were no events in one of the groups when dichotomizing based on 6.5. The high 522 and low mRNA abundance groups were compared by univariate log-rank tests for overall survival. 523 TC and TAC mRNA abundance were evaluated independently. Survival modelling was performed 524 in the R statistical environment (v3.4.3) using the survival package (v2.42-3). The CNA univariate 525 survival analysis was conducted as follows. For each gene, we assessed whether more gains or 526 losses were apparent. The copy number status with a higher count was subsequently used to 527 separate patients into two groups: those with the chosen copy number status and the remaining 528 patients. The two groups were then used for overall survival modelling with log-rank tests in the 529 R statistical environment (v3.4.3) using the survival package (v2.42-3). 530 of YAP and TAZ (symbols YAP1, WWTR1) and their putative target genes were investigated in 536 individual tissues and ranked by statistical significance of correlation tests. Tissue-specific ranked 537 correlations of target genes were then integrated into two master lists of target genes of YAP and 538 TAZ, respectively, reflecting target genes that were consistently positively co-regulated with 539 corresponding transcripts across a significant subset of considered human tissues. We used the 540 robust rank aggregation (RRA) method developed by Kolde et al 37 and filtered co-expressed genes by significance using the default parameters of RRA (Qgene<0.05). Significantly enriched 542 pathways among the putative target genes of YAP and TAZ were detected using ActivePathways. 543
Co-expression analysis of
We validated the pathways by investigating their agreement with known Hippo-related genes from 544 recent review papers 35, 36 . We tested each pathway for enrichment of literature-derived Hippo 545 genes using Fisher's exact tests and filtered significant findings after multiple testing correction 546 (Q<0.05). 547
Method benchmarking. We benchmarked ActivePathways using multiple approaches, including 548 simulated datasets, parameter variations, and partial replacement of strong scores with missing 549 values. Benchmarking was carried out with the PCAWG dataset of coding and non-coding cancer 550 driver predictions. To evaluate false discovery rates of ActivePathways, we created simulated 551 datasets by randomly reassigning all observed driver scores to random genes and genomic 552 elements. Simulations were conducted separately for different tumor cohorts. One thousand 553 simulated datasets were analyzed with ActivePathways and those with at least one significantly 554 detected pathway counted towards false discovery rates. Additional simulations maintained the 555 positions of non-coding driver scores among gene scores and randomly reassigned protein-556 coding driver scores, expectedly leading to a reduction in detected pathways as the input datasets 557 primarily included strong scores in protein-coding gene regions. Quantile-quantile analysis and 558 QQ-plots were used to compare p-value distributions of pathways discovered from true driver 559 scores, driver scores with shuffled driver scores, and driver scores shuffled entirely. To evaluate 560 robustness of ActivePathways, we randomly replaced a fraction of significant driver p-values in 561 input matrices (P<0.001) with insignificant p-values (P=1). We tested different fractions of missing 562 values (10%, 25%, 50%) across a thousand datasets of driver scores with randomly selected 563 missing data points and concluded that most cohorts included significantly enriched pathways 564 even with large fractions of missing data. To further evaluate robustness, we tested different 565 values of the Brown P-value threshold used to select the integrated gene list for pathway 566 enrichment analysis. The default parameter value (Pgene<0.1) was compared to alternative values 567 (0.001, 0.01, 0.05, 0.2). We concluded that ActivePathways found enriched pathways in most 568 tumor cohorts even at more stringent gene selection levels. 569
Availability. ActivePathways is freely available as an R package and source code on the GitHub 570 repository https://github.com/reimandlab/ActivePathways and the Comprehensive R Archive 571 Network (CRAN). 572 573
